Application of Nanobiotechnology for Early Diagnosis of SARS-CoV-2 Infection in the COVID-19 Pandemic.
2019-nCoV
Biosensor
COVID-19
Early diagnosis
Nanobiotechnology
Pandemic
SARS-CoV-2
Journal
Applied microbiology and biotechnology
ISSN: 1432-0614
Titre abrégé: Appl Microbiol Biotechnol
Pays: Germany
ID NLM: 8406612
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
05
10
2020
accepted:
24
02
2021
revised:
15
02
2021
pubmed:
13
3
2021
medline:
7
4
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
A most discussed topic of the new decade, COVID-19 is an infectious disease caused by the recently discovered SARS-CoV-2. With an exceedingly high transmission rate, COVID-19 has affected almost all the countries in the world. Absent any vaccine or specific treatment, the humanity is left with nothing but the legacy method of quarantine. However, quarantine can only be effective when combined with early diagnosis of suspected cases. With their high sensitivity and unmatched specificity, biosensors have become an area of interest for development of novel diagnostic methods. Compared to the more traditional diagnostics, nanobiotechnology introduces biosensors as different diagnostics with greater versatility in application. Today, a growing number of analytes are being accurately identified by these nanoscopic sensing machines. Several reports of validated application with real samples further strengthen this idea. As of recent, there has been a rise in the number of studies on portable biosensors. Despite the slow progression, certain devices with embedded biosensors have managed to be of diagnostic value in several countries. The perceptible increase in development of mobile platforms has revolutionized the healthcare delivery system in the new millennium. The present article reviews the most recent advancements in development of diagnostic nanobiosensors and their application in the clinical fields. KEY POINTS: • There is no specific treatment for highly transmissible SARS-CoV-2. • Early diagnosis is critical for control of pandemic. • Highly sensitive/specific nanobiosensors are emerging assets against COVID-19.
Identifiants
pubmed: 33710356
doi: 10.1007/s00253-021-11197-y
pii: 10.1007/s00253-021-11197-y
pmc: PMC7952259
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2615-2624Subventions
Organisme : Zahedan University of Medical Sciences
ID : IR.ZAUMS.REC.1399.197
Références
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nat Mater. 2008 Jun;7(6):442-53
pubmed: 18497851
Nat Chem. 2012 Jan 22;4(3):208-14
pubmed: 22354435
ACS Nano. 2020 Apr 28;14(4):5135-5142
pubmed: 32293168
Biosensors (Basel). 2019 May 21;9(2):
pubmed: 31117262
Expert Rev Mol Diagn. 2019 Jan;19(1):71-81
pubmed: 30513011
Trends Analyt Chem. 2013 Jun;47:27-36
pubmed: 32287538
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:110007
pubmed: 31500008
Sci Transl Med. 2017 Oct 4;9(410):
pubmed: 28978750
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
ACS Nano. 2020 May 26;14(5):5268-5277
pubmed: 32281785
N Engl J Med. 2005 Sep 29;353(13):1363-73
pubmed: 16192481
Nano Lett. 2019 Mar 13;19(3):1437-1444
pubmed: 30757905
J Cyst Fibros. 2018 Jul;17(4):e35-e38
pubmed: 29580829
J Appl Microbiol. 2018 Mar;124(3):626-643
pubmed: 29165905
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Biosens Bioelectron. 2017 Jan 15;87:701-707
pubmed: 27636559
ACS Sens. 2019 May 24;4(5):1306-1312
pubmed: 31062580
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Nat Chem. 2018 Jan;10(1):91-98
pubmed: 29256499
J Control Release. 2021 Feb 10;330:49-60
pubmed: 33340564
Lancet. 2020 Mar 21;395(10228):e52
pubmed: 32171074
Annu Rev Phys Chem. 2007;58:267-97
pubmed: 17067281
BMJ. 2020 Feb 18;368:m641
pubmed: 32071063
Mater Sci Eng C Mater Biol Appl. 2013 Mar 1;33(2):824-30
pubmed: 25427493
Sensors (Basel). 2012;12(9):12506-18
pubmed: 23112728
Sci Transl Med. 2017 May 3;9(388):
pubmed: 28469032
Epidemiology. 2005 Nov;16(6):791-801
pubmed: 16222170
Biosens Bioelectron. 2020 Oct 15;166:112437
pubmed: 32692666
J Cell Physiol. 2020 Dec;235(12):8873-8924
pubmed: 32452539
J Immunol Methods. 2009 Oct 31;350(1-2):118-24
pubmed: 19682995
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20701-4
pubmed: 19075225
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
J Clin Microbiol. 2010 Aug;48(8):2872-7
pubmed: 20554831
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
J Am Chem Soc. 2005 Feb 23;127(7):2264-71
pubmed: 15713105
Radiology. 2020 Aug;296(2):E41-E45
pubmed: 32049601
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508